[go: up one dir, main page]

AR119507A1 - Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 - Google Patents

Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3

Info

Publication number
AR119507A1
AR119507A1 ARP200102112A ARP200102112A AR119507A1 AR 119507 A1 AR119507 A1 AR 119507A1 AR P200102112 A ARP200102112 A AR P200102112A AR P200102112 A ARP200102112 A AR P200102112A AR 119507 A1 AR119507 A1 AR 119507A1
Authority
AR
Argentina
Prior art keywords
antibodies
lag3
trispecific
tigit
bispecific
Prior art date
Application number
ARP200102112A
Other languages
English (en)
Inventor
Laurence Fayadat-Dilman
Veronica Juan
Robert A Kastelein
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR119507A1 publication Critical patent/AR119507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan tratamientos de condiciones que se mejoran al contrarrestar la supresión inmunitaria mediada por tumores. Más específicamente, en la presente se proporcionan anticuerpos triespecíficos anti-PD-1 / LAG-3 / TIGIT, anticuerpos biespecíficos anti-PD-1 / LAG3, anticuerpos anti-LAG3 y fragmentos de fijación al antígeno. En la presente también se proporcionan métodos y usos de estos anticuerpos y fragmentos de fijación al antígeno en el tratamiento del cáncer o de una enfermedad infecciosa.
ARP200102112A 2019-07-30 2020-07-28 Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 AR119507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962880158P 2019-07-30 2019-07-30

Publications (1)

Publication Number Publication Date
AR119507A1 true AR119507A1 (es) 2021-12-22

Family

ID=74230796

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102112A AR119507A1 (es) 2019-07-30 2020-07-28 Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3

Country Status (5)

Country Link
US (1) US20220251194A1 (es)
EP (1) EP4003523A4 (es)
JP (1) JP2022546922A (es)
AR (1) AR119507A1 (es)
WO (1) WO2021021767A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963560A (zh) * 2016-10-28 2019-07-02 默沙东公司 用于除去酪氨酸硫酸化抗体变体的纯化方法、经纯化的组合物
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
CN120590537A (zh) * 2021-12-31 2025-09-05 南京维立志博生物科技股份有限公司 靶向tigit的双特异性抗体
TW202430556A (zh) * 2022-12-16 2024-08-01 美商默沙東有限責任公司 治療癌症患者之pd-1拮抗劑、tigit拮抗劑及結合191p4d12蛋白之抗體藥物結合物之組合療法
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025016012A1 (en) * 2023-07-14 2025-01-23 Genor Biopharma Co., Ltd. Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
JP5320546B2 (ja) * 2006-12-13 2013-10-23 国立大学法人名古屋大学 Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8034992B2 (en) * 2008-06-16 2011-10-11 Academia Sinica Gibberellin 2-oxidase genes and uses thereof
SI3021869T1 (sl) * 2013-07-16 2020-10-30 F. Hoffmann-La Roche Ag Postopki zdravljenja raka z uporabo antagonistov in inhibitorjev TIGIT, ki se vežejo na os PD-1
PE20170289A1 (es) * 2014-08-19 2017-04-05 Merck Sharp & Dohme Anticuerpos anti tigit
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US20170097333A1 (en) * 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US11285207B2 (en) * 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
MX2019013072A (es) * 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
US20200369770A1 (en) * 2018-01-08 2020-11-26 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Also Published As

Publication number Publication date
US20220251194A1 (en) 2022-08-11
WO2021021767A1 (en) 2021-02-04
JP2022546922A (ja) 2022-11-10
EP4003523A4 (en) 2023-09-06
EP4003523A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AR119507A1 (es) Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
MX2023004333A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2018001596A (es) Anticuerpos anti-receptor ccr7 humanizados.
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
JOP20190055A1 (ar) أجسام مضادة ضد cd27
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
MX384790B (es) Anticuerpos anti-tau humanizados.
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2018014610A (es) Uso de un anticuerpo anti proteina de muerte programada 1 (pd-1) en combinacion con un anticuerpo anti cumulo de diferenciacion 3d (cd30) en el tratamiento del linfoma.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
MX2020009296A (es) Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
EA202190647A1 (ru) Антитела к klrg1
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal